EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Benign COVID-19 in an Aggressive Case of Aquaporin-4 Neuromyelitis Optica Treated with Tocilizumab

Domizia Vecchio, Claudio Solaro, Eleonora Virgilio, Paola Naldi, Rugiada Bottero, Fabio Masuccio, Marco Capobianco, Roberto Cantello

Sclerosis · 2022

DOI: 10.3390/sclerosis1010001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sclerosis, 2022. Verfasst von Domizia Vecchio und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aggressive neuromyelitis optica spectrum disorders (NMOSDs) with antibodies (Abs) against aquaporin-4 (AQP4) can be treated by blocking the interleukin 6 (IL6) pathways with tocilizumab. This IL6-inhibitor was employed to treat coronavirus disease 2019 (COVID-19) pneumonia with unconclusive results. We present a 52-year-old woman with AQP4 NMOSD, unresponsive to rituximab, that stabilized on tocilizumab one year after the disease onset. She was bed-bound and progressively recovered her mobility. During intensive rehabilitation, she presented fever and cough for one week with nasopharyngeal swabs positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This mild COVID-19 recovered spontaneously without sequelae, and the monthly tocilizumab infusions were continued for another 10 months. Subsequently, serious and prolonged respiratory and urinary infections caused treatment interruption, and then her disease re-activated. In our case, tocilizumab was effective in preventing NMOSD relapse and was safe to use during SARS-CoV-2 infection.

Zitieren

APA

Vecchio, D., Solaro, C., Virgilio, E., Naldi, P., Bottero, R., Masuccio, F., Capobianco, M., & Cantello, R. (2022). Benign COVID-19 in an Aggressive Case of Aquaporin-4 Neuromyelitis Optica Treated with Tocilizumab. Sclerosis. https://doi.org/10.3390/sclerosis1010001

Vancouver

Vecchio D, Solaro C, Virgilio E, Naldi P, Bottero R, Masuccio F, et al. Benign COVID-19 in an Aggressive Case of Aquaporin-4 Neuromyelitis Optica Treated with Tocilizumab. Sclerosis. 2022. doi:10.3390/sclerosis1010001

BibTeX
@article{Vecchio2022,
  author = {Vecchio, Domizia and Solaro, Claudio and Virgilio, Eleonora and Naldi, Paola and Bottero, Rugiada and Masuccio, Fabio and Capobianco, Marco and Cantello, Roberto},
  title = {Benign COVID-19 in an Aggressive Case of Aquaporin-4 Neuromyelitis Optica Treated with Tocilizumab},
  journal = {Sclerosis},
  year = {2022},
  doi = {10.3390/sclerosis1010001}
}
Kostenlos starten →